Literature DB >> 32389660

Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate.

Christopher M Heaphy1, Michael C Haffner2, Mindy K Graham3, David Lim4, Christine Davis2, Eva Corey5, Jonathan I Epstein6, Mario A Eisenberger7, Hao Wang4, Angelo M De Marzo6, Alan K Meeker6, Tamara L Lotan6.   

Abstract

Small-cell neuroendocrine carcinoma (SCNC) of the prostate is an aggressive subtype with frequent TP53 mutation and RB1 inactivation; however, the molecular phenotype remains an area of investigation. Here, we compared telomere lengths in prostatic SCNC and usual-type prostatic adenocarcinoma (AdCa). We studied 32 cases of prostatic SCNC (including 11 cases with concurrent AdCa) and 347 cases of usual-type AdCa on tissue microarrays. Telomere lengths in tumor cells were qualitatively compared with those in normal cells using a telomere-specific fluorescence in situ hybridization assay. ERG, PTEN, and TP53 status were assessed in a proportion of cases using genetically validated immunohistochemistry protocols. Clinicopathological and molecular characteristics of cases were compared between the telomere groups using the chi-square test.A significantly higher proportion of prostatic SCNC cases (50%, 16/32) showed normal/long telomeres compared with AdCa cases (11%, 39/347; P < 0.0001). In 82% (9/11) of cases with concurrent SCNC and AdCa, the paired components were concordant for telomere length status. Among AdCa cases, the proportion of cases with normal/long telomeres significantly increased with increasing tumor grade group (P = 0.01) and pathologic stage (P = 0.02). Cases with normal/long telomeres were more likely to be ERG positive (P = 0.04) and to have TP53 missense mutation (P = 0.01) than cases with short telomeres.Normal or long telomere lengths are significantly more common in prostatic SCNC than in AdCa and are similar between concurrent SCNC and AdCa tumors, supporting a common origin. Among AdCa cases, longer telomere lengths are significantly associated with high-risk pathologic and molecular features.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma; Neuroendocrine; Prostate cancer; Small-cell carcinoma; Telomeres

Mesh:

Year:  2020        PMID: 32389660      PMCID: PMC7321874          DOI: 10.1016/j.humpath.2020.04.014

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  57 in total

1.  Telomere end-replication problem and cell aging.

Authors:  M Z Levy; R C Allsopp; A B Futcher; C W Greider; C B Harley
Journal:  J Mol Biol       Date:  1992-06-20       Impact factor: 5.469

Review 2.  Structure and function of telomeres.

Authors:  E H Blackburn
Journal:  Nature       Date:  1991-04-18       Impact factor: 49.962

3.  PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.

Authors:  Carlos L Morais; Mehsati Herawi; Antoun Toubaji; Roula Albadine; Jessica Hicks; George J Netto; Angelo M De Marzo; Jonathan I Epstein; Tamara L Lotan
Journal:  Prostate       Date:  2015-07-14       Impact factor: 4.104

4.  Shorter telomeres in luminal B, HER-2 and triple-negative breast cancer subtypes.

Authors:  Christopher M Heaphy; Andrea Proctor Subhawong; Amy L Gross; Yuko Konishi; Nina Kouprina; Pedram Argani; Kala Visvanathan; Alan K Meeker
Journal:  Mod Pathol       Date:  2010-11-05       Impact factor: 7.842

5.  Short telomeres limit tumor progression in vivo by inducing senescence.

Authors:  David M Feldser; Carol W Greider
Journal:  Cancer Cell       Date:  2007-04-12       Impact factor: 31.743

6.  Systematic analysis of telomere length and somatic alterations in 31 cancer types.

Authors:  Floris P Barthel; Wei Wei; Ming Tang; Emmanuel Martinez-Ledesma; Xin Hu; Samirkumar B Amin; Kadir C Akdemir; Sahil Seth; Xingzhi Song; Qianghu Wang; Tara Lichtenberg; Jian Hu; Jianhua Zhang; Siyuan Zheng; Roel G W Verhaak
Journal:  Nat Genet       Date:  2017-01-30       Impact factor: 38.330

7.  Telomere length as a risk factor for hereditary prostate cancer.

Authors:  Lauren M Hurwitz; Christopher M Heaphy; Corinne E Joshu; William B Isaacs; Yuko Konishi; Angelo M De Marzo; Sally D Isaacs; Kathy E Wiley; Elizabeth A Platz; Alan K Meeker
Journal:  Prostate       Date:  2013-11-28       Impact factor: 4.104

8.  Prostate cancer cell telomere length variability and stromal cell telomere length as prognostic markers for metastasis and death.

Authors:  Christopher M Heaphy; Ghil Suk Yoon; Sarah B Peskoe; Corinne E Joshu; Thomas K Lee; Edward Giovannucci; Lorelei A Mucci; Stacey A Kenfield; Meir J Stampfer; Jessica L Hicks; Angelo M De Marzo; Elizabeth A Platz; Alan K Meeker
Journal:  Cancer Discov       Date:  2013-06-18       Impact factor: 39.397

9.  Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.

Authors:  Donna E Hansel; Masashi Nakayama; Jun Luo; Abde M Abukhdeir; Ben H Park; Charles J Bieberich; Jessica L Hicks; Mario Eisenberger; William G Nelson; Jasek L Mostwin; Angelo M De Marzo
Journal:  Prostate       Date:  2009-05-01       Impact factor: 4.104

10.  Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.

Authors:  Jonathan I Epstein; Mahul B Amin; Himisha Beltran; Tamara L Lotan; Juan-Miguel Mosquera; Victor E Reuter; Brian D Robinson; Patricia Troncoso; Mark A Rubin
Journal:  Am J Surg Pathol       Date:  2014-06       Impact factor: 6.394

View more
  1 in total

1.  Race Differences in Telomere Length in Benign Prostate Biopsies and Subsequent Risk of Prostate Cancer.

Authors:  Benjamin A Rybicki; Sudha M Sadasivan; Yalei Chen; Ian Loveless; Nilesh S Gupta; Dhananjay A Chitale; Sean R Williamson; Andrew G Rundle; Deliang L Tang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-05-04       Impact factor: 4.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.